Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
UroGen Pharma Ltd. (URGN)
|
Add to portfolio |
|
|
|
| Price: |
$17.48
| | Metrics |
| OS: |
30.3
|
M
| |
|
|
| Market cap: |
$529
|
M
| |
-155
|
% ROIC
|
|
Net debt:
|
$43
|
M
| |
|
|
|
EV:
|
$572
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($74.9)
|
M
| |
|
|
|
EBIT
|
($75.8)
|
M
| |
|
|
| EPS |
($4.73)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 64.4 | 48.0 | 11.8 | 0.0 | 1.1 | 8.2 | 17.5 | 0.0 |
| Revenue growth | 34.0% | 307.2% | 65450.0% | -98.4% | -86.2% | -53.5% | | |
| Cost of goods sold | 7.7 | 5.2 | 1.0 | 0.0 | 1.8 | 0.6 | 0.0 | 0.0 |
| Gross profit | 56.7 | 42.9 | 10.8 | 0.0 | -0.7 | 7.6 | 17.5 | 0.0 |
| Gross margin | 88.1% | 89.3% | 91.4% | 100.0% | -59.8% | 92.6% | 99.8% | |
| Selling, general and administrative | 82.8 | 87.5 | 90.2 | 60.2 | | | | |
| Research and development | 52.9 | 47.6 | 47.3 | 49.3 | 36.9 | 18.7 | 10.3 | 10.5 |
| General and administrative | | | | | 39.6 | 8.8 | 6.4 | 1.9 |
| EBIT | -79.0 | -92.3 | -126.7 | -109.5 | -77.2 | -20.0 | 0.8 | -12.4 |
| EBIT margin | -122.8% | -192.1% | -1074.2% | -608211.1% | -6842.2% | -244.5% | 4.6% | |
| Pre-tax income | -108.0 | -109.4 | -125.1 | -105.1 | -75.5 | -20.0 | -1.9 | -12.7 |
| Income taxes | 1.8 | 1.4 | 3.4 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | 0.0% | | | 0.0% | 0.0% |
| Net income | -109.8 | -110.8 | -128.5 | -105.1 | -75.7 | -20.0 | -1.9 | -12.7 |
| Net margin | -170.6% | -230.7% | -1088.9% | -584144.4% | -6707.2% | -245.2% | -11.1% | |
| |
| Diluted EPS | ($4.81) | ($4.96) | ($5.90) | ($5.12) | ($4.80) | ($2.06) | ($0.84) | ($5.51) |
| Shares outstanding (diluted) | 22.8 | 22.3 | 21.8 | 20.5 | 15.8 | 9.7 | 2.3 | 2.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|